powassan
viru
powv
emerg
ticktransmit
flaviviru
circul
north
america
russia
deer
tick
test
posit
powv
certain
region
northern
unit
state
although
powv
infect
caus
lifethreaten
enceph
vaccin
countermeasur
avail
prevent
treatment
develop
lipid
nanoparticl
lnp
encapsul
modifi
mrna
vaccin
encod
powv
prm
e
gene
demonstr
immunogen
efficaci
mice
follow
immun
one
two
dose
powv
mrna
vaccin
induc
high
titer
neutral
antibodi
steril
immun
lethal
challeng
differ
powv
strain
mrna
vaccin
also
induc
crossneutr
antibodi
multipl
tickborn
flavivirus
protect
mice
distantli
relat
langat
viru
data
demonstr
util
lnpmrna
open
access
articl
cc
byncnd
licens
vaccin
platform
develop
vaccin
protect
activ
multipl
flavivirus
two
genet
lineag
powv
circul
north
america
lineag
lineag
ii
also
call
deertick
viru
dtv
although
serolog
clinic
indistinguish
share
least
amino
acid
ident
envelop
e
protein
ebel
et
al
powv
lineag
strain
predominantli
maintain
ixod
cookei
tick
includ
isol
new
york
canada
wherea
lineag
ii
strain
found
ixod
scapulari
deer
tick
includ
strain
region
infest
tick
ebel
et
al
deer
tick
aggress
bite
human
lineag
ii
virus
may
greater
epidem
potenti
although
powv
found
predominantli
northcentr
northeastern
part
unit
state
ixod
speci
tick
powv
also
isol
dermacentor
andersoni
tick
colorado
thoma
et
al
indic
vector
geograph
rang
may
larger
previous
estim
tbfv
divid
three
group
mammalian
group
seabird
group
kadam
viru
group
grard
et
al
mammalian
tbfv
group
includ
powv
sever
human
pathogen
includ
tickborn
enceph
viru
tbev
omsk
hemorrhag
fever
viru
ohfv
kyasanur
forest
diseas
viru
kfdv
alkhurma
hemorrhag
fever
viru
ahfv
within
e
protein
mammalian
tbfv
group
share
amino
acid
ident
ident
seabird
tbfv
one
except
gadget
gulli
viru
ggyv
close
relat
mammalian
tbfv
even
though
caus
infect
seabird
grard
et
al
vaccin
develop
sever
mammalian
tbfv
although
tbev
vaccin
proven
efficaci
ishikawa
et
al
tbev
vaccin
induc
antibodi
capabl
neutral
close
relat
tbfv
includ
ohfv
kfdv
ahfv
mcauley
et
al
howev
tbev
immun
sera
limit
crossneutr
activ
distantli
relat
powv
approv
vaccin
powv
exist
lack
powvspecif
vaccin
limit
induct
crossneutr
antibodi
tbfv
vaccin
epidem
potenti
powv
prompt
us
design
vaccin
test
immunogen
efficaci
select
vaccin
platform
develop
distantli
relat
flaviviru
zika
viru
zikv
lipid
nanoparticl
lnp
encapsul
modifi
mrna
encod
structur
premembran
prm
e
protein
gene
richner
et
al
coexpress
flaviviru
structur
protein
prm
e
result
secret
subvir
particl
svp
share
mani
function
antigen
featur
infecti
virion
elicit
neutral
antibodi
svp
heterogen
size
like
display
e
protein
distinct
chemic
environ
potenti
affect
epitop
display
heinz
et
al
kiermayr
et
al
konishi
fujii
konishi
et
al
addit
select
powv
prme
structur
gene
compon
use
mrna
platform
modifi
mrna
report
enhanc
follicular
helper
cell
germin
center
b
cell
respons
essenti
induc
memori
b
cell
durabl
level
neutral
antibodi
pardi
et
al
describ
lnpencapsul
modifi
mrna
vaccin
encod
prme
powv
induc
potent
neutral
antibodi
respons
mice
protect
lethal
viral
challeng
strain
powv
lineag
furthermor
powv
mrna
vaccin
induc
crossneutr
antibodi
titer
tbfv
confer
protect
diseas
follow
challeng
mice
distantli
relat
langat
viru
lgtv
plan
vaccin
efficaci
studi
develop
challeng
model
powv
infect
adult
mice
although
other
describ
murin
model
powv
infect
juvenil
mice
week
old
ideal
experi
requir
iter
immun
rest
period
hermanc
thangamani
holbrook
et
al
mlera
et
al
santo
et
al
wang
et
al
accordingli
test
abil
two
powv
strain
lb
lineag
strain
spooner
lineag
ii
dtv
strain
caus
morbid
mortal
wildtyp
wt
mice
week
age
follow
subcutan
inocul
focusform
unit
ffu
powv
lb
lethal
infect
ensu
mice
mean
time
death
day
postinfect
dpi
respect
figur
mice
inocul
powv
lb
lost
approxim
bodi
weight
figur
powv
lbinfect
mice
exhibit
ruffl
fur
hunch
postur
lethargi
partial
paralysi
although
mice
exhibit
sign
death
figur
comparison
powv
spooner
result
lower
mortal
rate
mice
succumb
infect
mean
time
death
day
respect
figur
partial
lethal
caus
powv
spooner
wt
mice
creat
suscept
host
transient
block
type
interferon
ifn
signal
antiifn
receptor
monoclon
antibodi
mab
sheehan
et
al
mg
mab
administ
one
day
infect
powv
spooner
result
lethal
mean
time
death
day
figur
wherea
powv
spoonerinfect
wt
mice
typic
display
bodi
weight
loss
infect
mice
treat
mab
sustain
greater
weight
loss
figur
powv
spoonerinfect
wt
mice
display
ruffl
fur
hunch
postur
lethargi
minor
develop
limb
paralysi
figur
comparison
mabtreat
powv
spoonerinfect
mice
uniformli
display
sign
morbid
death
develop
lethal
challeng
model
older
mice
engin
lnpencapsul
modifi
mrna
vaccin
powv
base
prme
construct
develop
zikv
richner
et
al
richner
et
al
design
basemodifi
mrna
encod
prm
e
gene
powv
spooner
preced
prm
signal
sequenc
powv
powv
sig
signal
sequenc
jev
jev
sig
latter
heterolog
jev
signal
sequenc
test
flavivirus
result
enhanc
secret
svp
davi
et
al
dowd
et
al
sixweekold
wt
mice
immun
powv
sig
jev
sig
placebo
lnp
intramuscular
inocul
follow
second
mg
booster
dose
day
later
figur
serum
collect
preboost
day
postboost
day
neutral
activ
assess
report
viru
particl
rvp
assay
use
cprme
protein
powv
lineag
ii
strain
rajisignr
cell
mukherje
et
al
rvp
technolog
use
extens
preclin
clinic
evalu
flaviviru
vaccin
candid
emanuel
et
al
gaudinski
et
al
pardi
et
al
richner
et
al
follow
first
dose
reciproc
mean
titer
reduc
rvp
infect
maxim
effect
inhibitori
concentr
ec
valu
n
n
powv
sig
jev
sig
respect
statist
differ
two
formul
p
neutral
titer
boost
approxim
follow
second
dose
formul
ec
valu
n
powv
sig
n
jev
sig
despit
high
ec
valu
first
dose
neutralizationresist
fraction
observ
formul
howev
fraction
reduc
follow
booster
dose
p
vaccin
figur
subset
postboost
sera
day
test
neutral
potenc
second
assay
focusreduct
neutral
test
frnt
vero
cell
gener
lower
ec
valu
observ
frnt
rvp
neutral
assay
report
zikv
nonetheless
powv
sig
jev
sig
induc
robust
frnt
titer
n
n
respect
powv
spooner
figur
furthermor
virtual
resist
fraction
observ
frnt
valu
n
n
powv
sig
jev
sig
respect
figur
two
contemporari
lineag
ii
viru
strain
powv
isol
tick
collect
wisconsin
passag
cell
well
lineag
powv
lb
strain
also
neutral
effici
serum
powv
sig
jev
sig
vaccin
mice
measur
frnt
figur
follow
twodos
vaccin
schedul
mice
challeng
via
subcutan
inocul
ffu
powv
spooner
powv
lb
day
postboost
figur
powv
spoonerchalleng
mice
treat
one
day
infect
mg
mab
achiev
high
mortal
rate
placebotr
mice
challeng
mice
monitor
surviv
weight
loss
day
serum
sampl
collect
two
day
postchalleng
assay
viremia
follow
powv
spooner
challeng
mabtreat
mice
expect
placebovaccin
mice
succumb
infect
comparison
powv
sig
jev
sig
vaccin
mice
surviv
challeng
figur
furthermor
powv
sig
jev
sig
vaccin
mice
maintain
bodi
weight
wherea
placebovaccin
mice
lost
weight
figur
consist
data
high
level
viremia
measur
placebovaccin
mice
powv
sig
jev
sig
vaccin
mice
figur
similar
result
observ
follow
powv
lb
challeng
absenc
mab
treatment
wherea
placebovaccin
mice
succumb
follow
lb
infect
powv
sig
jev
sig
vaccin
mice
surviv
infect
figur
placebovaccin
mice
lost
bodi
weight
wherea
powv
sig
jev
sigvaccin
mice
maintain
weight
follow
viru
challeng
figur
addit
viremia
undetect
powv
sig
jev
sig
vaccin
mice
present
placebovaccin
mice
figur
thu
mrna
vaccin
formul
protect
lethal
powv
challeng
strain
lineag
assess
role
humor
immun
respons
mediat
protect
powv
challeng
passiv
transfer
serum
powv
sig
vaccin
postboost
day
placebotr
mice
naiv
mice
one
day
inocul
ffu
powv
lb
wherea
mice
receiv
serum
placebotr
mice
succumb
powv
lb
challeng
mice
receiv
serum
respect
powv
sig
vaccin
mice
succumb
viral
challeng
figur
furthermor
mice
surviv
viral
challeng
follow
passiv
transfer
powv
sig
serum
respect
exhibit
weight
loss
follow
viral
challeng
wherea
mice
receiv
serum
placebotr
mice
lost
bodi
weight
passiv
transfer
serum
vaccin
mice
result
signific
reduct
viremia
dpi
mice
receiv
powv
sig
serum
reduct
p
viremia
follow
challeng
compar
mice
receiv
serum
placebotr
mice
viremia
undetect
mice
receiv
powv
sig
serum
data
indic
humor
immun
respons
powv
sig
vaccin
suffici
protect
mice
lethal
powv
challeng
next
test
whether
singl
dose
powv
mrna
vaccin
suffici
protect
studi
immun
wt
mice
powv
sig
placebo
vaccin
twentyeight
day
later
mice
treat
mab
challeng
via
subcutan
inocul
ffu
powv
spooner
observ
previous
placeboimmun
mice
succumb
infect
lost
bodi
weight
figur
contrast
powv
sig
immun
mice
uniformli
surviv
challeng
maintain
bodi
weight
furthermor
viremia
detect
powv
sig
immun
mice
dpi
compar
high
level
placeboimmun
mice
figur
serum
sampl
collect
day
postchalleng
evalu
neutral
titer
ec
valu
significantli
differ
two
time
point
p
figur
mice
less
twofold
chang
titer
tabl
indic
littl
boost
antibodi
respons
occur
follow
viral
challeng
powv
sig
immun
mice
data
suggest
one
dose
mrna
vaccin
suffici
induc
protect
steril
immun
powv
challeng
powv
share
amino
acid
ident
e
protein
mammalian
tbfv
ident
seabird
tbfv
clade
figur
determin
abil
serum
powvvaccin
mice
inhibit
tbfv
test
sera
powv
sigor
jev
sig
vaccin
twodos
mice
capac
inhibit
tbev
lgtv
ggyv
rvp
figur
figur
tbev
chosen
overlap
geograph
powv
part
far
eastern
russia
leonova
et
al
leonova
et
al
larg
public
health
impact
infect
peopl
annual
europ
asia
gritsun
et
al
lgtv
select
due
related
tbev
prior
use
tbev
vaccin
mandl
et
al
ggyv
one
diverg
virus
mammalian
group
tbfv
grard
et
al
thu
demonstr
breadth
crossreact
respons
powv
vaccin
sera
powv
share
amino
acid
ident
e
protein
sequenc
lgtv
tbev
ggyv
vaccin
sera
neutral
infect
rvp
bear
e
protein
tbfv
although
sampl
neutral
ggyv
wherea
other
figur
variabl
neutral
ggyv
powv
vaccin
sera
warrant
studi
may
due
greater
sequenc
dissimilar
virus
figur
result
differenti
display
neutral
epitop
sera
powv
sig
vaccin
mice
exhibit
crossneutr
activ
mean
ec
valu
tbev
lgtv
ggyv
n
n
n
respect
jev
sig
induc
similar
crossneutr
titer
tbev
n
lgtv
n
ggyv
n
powv
mrna
vaccin
show
capac
vitro
neutral
tbfv
test
abil
powv
sig
vaccin
protect
lgtv
challeng
vivo
test
efficaci
powv
sig
vaccin
lgtv
tbev
ggyv
due
requir
facil
lack
exist
challeng
model
respect
follow
twodos
vaccin
schedul
figur
mice
challeng
via
subcutan
inocul
ffu
lgtv
day
postboost
lgtv
pathogen
mice
wt
mice
weber
et
al
treat
anim
mg
mab
one
day
viru
challeng
follow
lgtv
challeng
placebotr
mice
lost
bodi
weight
wherea
powv
sig
vaccin
mice
lost
bodi
weight
vaccin
mice
maintain
weight
figur
powv
sig
vaccin
mice
fulli
protect
clinic
diseas
wherea
placebotr
mice
exhibit
sign
paralysi
one
mous
succumb
lgtv
challeng
figur
powv
sig
vaccin
mice
significantli
less
viremia
placebotr
mice
dpi
reduct
viral
titer
p
figur
powv
sig
vaccin
mice
also
substanti
less
viral
rna
spleen
brain
spinal
cord
day
postlgtv
challeng
p
comparison
figur
thu
powv
sig
vaccin
induc
immun
respons
protect
heterolog
challeng
lgtv
frequenc
epidem
caus
emerg
reemerg
virus
zikv
chikungunya
viru
ebola
viru
middl
east
respiratori
syndrom
coronaviru
lack
prepared
public
health
crise
highlight
need
develop
versatil
vaccin
platform
rapidli
manufactur
deploy
variou
viral
threat
advantag
lnpencapsul
modifi
mrna
platform
allow
rapid
develop
vaccin
candid
insert
desir
viral
mrna
sequenc
code
region
studi
use
mrna
vaccin
platform
previous
shown
effect
mice
zikv
pardi
et
al
richner
et
al
develop
countermeasur
powv
anoth
emerg
flaviviru
hermanc
thangamani
vaccin
mice
lnpencapsul
mrnaencod
powv
structur
gene
induc
potent
neutral
antibodi
respons
protect
challeng
powv
strain
lineag
furthermor
one
dose
powv
mrna
vaccin
suffici
induc
robust
immun
viremia
signific
anamnest
antibodi
respons
observ
follow
powv
challeng
antibodi
respons
induc
powv
mrna
vaccin
broadli
neutral
infect
panel
tbfv
includ
lgtv
tbev
ggyv
tbfv
differ
powv
e
protein
sequenc
approxim
neutral
titer
lowest
ggyv
distantli
relat
tbfv
test
furthermor
powv
mrna
vaccin
protect
mice
diseas
follow
lgtv
challeng
indic
vaccin
inhibitori
activ
multipl
tbfv
although
durabl
crossprotect
respons
warrant
test
result
contrast
prior
studi
observ
littl
crossreact
sera
tbevinfect
tbevvaccin
human
powv
mcauley
et
al
appar
dispar
result
may
sever
reason
antibodi
repertoir
produc
mice
versu
human
respons
tbfv
may
crossreact
mous
human
antibodi
specif
tbev
immun
differ
jarmer
et
al
notwithstand
data
mous
immun
ascit
fluid
rais
tbfv
tbev
ohfv
kfdv
neutral
powv
mcauley
et
al
furthermor
separ
studi
evalu
tbev
vaccin
mice
observ
littl
crossneutr
powv
antibodi
titer
crossprotect
powv
challeng
vivo
chernokhaeva
et
al
remain
possibl
direction
crossreact
respons
powv
induc
crossreact
antibodi
tbev
tbfv
due
differenti
display
conserv
epitop
altern
svp
induc
mrna
vaccin
may
display
crossreact
epitop
inactiv
fulli
infecti
tbev
virion
due
differ
arrang
e
protein
svp
compar
virion
kiermayr
et
al
kuhn
et
al
studi
compar
antibodi
repertoir
induc
lnpmrna
vaccin
gener
live
viru
infect
inactiv
viru
vaccin
could
address
question
addit
rvpbase
assay
use
assess
neutral
titer
tbev
may
sensit
plaquereduct
neutral
test
prnt
use
other
observ
increas
sensit
rvpbase
neutral
assay
compar
frnt
powv
howev
reciproc
result
true
lgtv
studi
anoth
explan
differ
crossneutr
respons
could
time
serum
sampl
evalu
neutral
potenc
sera
collect
day
postvaccin
wherea
mcauley
colleagu
test
sera
collect
month
postvaccin
month
postinfect
mcauley
et
al
although
previou
studi
show
antizikv
antibodi
respons
lnpencapsul
mrna
vaccin
endur
least
five
month
postvaccin
pardi
et
al
durabl
breadth
powv
lnpmrna
antibodi
respons
warrant
studi
may
appli
particularli
crossreact
antibodi
respons
antiflaviviru
antibodi
respons
gener
longliv
plasma
cell
memori
b
cell
compart
context
west
nile
viru
wnv
infect
typespecif
repertoir
purtha
et
al
moreov
previou
studi
zikv
dengu
viru
denv
found
crossneutr
antibodi
respons
flaviviru
infect
greatest
earlyconvalesc
stage
month
wane
time
collin
et
al
montoya
et
al
chernokhaeva
colleagu
challeng
mice
powv
four
week
follow
immun
tbev
observ
crossprotect
chernokhaeva
et
al
neutral
antibodi
respons
establish
correl
protect
follow
vaccin
sever
flavivirus
includ
yellow
fever
viru
japanes
enceph
viru
tbev
belmustoworn
et
al
heinz
et
al
mason
et
al
monath
et
al
like
contribut
protect
follow
immun
powv
lnpmrna
vaccin
passiv
transfer
serum
powv
lnpmrnavaccin
mice
suffici
protect
lethal
powv
challeng
howev
lnpmrna
zikv
vaccin
describ
pardi
colleagu
induc
strong
antigenspecif
cell
respons
addit
neutral
antibodi
pardi
et
al
although
character
cell
respons
powv
mrnalnp
vaccin
insight
immunodomin
hierarchi
tetramerspecif
reagent
lack
similar
cell
respons
gener
could
contribut
protect
powv
lgtv
challeng
summari
show
lnpmrna
vaccin
platform
readili
adapt
develop
vaccin
anoth
flaviviru
powv
epidem
potenti
highlight
util
platform
develop
vaccin
variou
flavivirus
mosquitoborn
tickborn
group
point
potenti
optim
adapt
immun
respons
broadli
protect
multipl
virus
inform
request
resourc
reagent
direct
fulfil
lead
contact
michael
diamond
diamond
wusmwustledu
cellscel
line
maintain
c
presenc
cell
passag
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fetal
bovin
serum
fb
omega
scientif
uml
penicillinstreptomycin
ps
invitrogen
vero
cell
passag
dmem
supplement
fb
uml
ps
raji
b
lymphoblast
cell
stabli
express
ctype
lectin
dcsignr
rajidcsignr
cultur
rpmi
medium
invitrogen
supplement
fb
uml
ps
washington
univers
anim
studi
committe
mice
purchas
jackson
laboratori
hous
pathogenfre
anim
facil
washington
univers
st
loui
male
femal
mice
vaccin
week
age
two
dose
studi
week
age
one
dose
studi
infect
powv
lgtv
week
age
week
indic
gener
modifi
mrna
lnpthe
mrna
synthes
vitro
use
dnadepend
rna
polymerasemedi
transcript
utp
substitut
linear
dna
templat
use
incorpor
untransl
region
utr
includ
polya
tail
gggaaauaagagagaaaagaagaguaagaagaaauauaagagccacc
gcuggagc
cucgguggccuagcuucuugccccuugggccuccccccagccccuccuccccu
uccugcacccguacccccguggucuuu
gaauaaagucugagugggcggc
final
mrna
util
cap
structur
modif
increas
mrna
translat
effici
encod
signal
sequenc
powv
prm
sgvdwtwtflvmalmt
jev
prm
mwlvslaivtacaga
prm
e
gene
deriv
powv
spooner
lnp
formul
prepar
ethanol
drop
nanoprecipit
microfluid
mixer
precis
nanosystem
briefli
lipid
dissolv
ethanol
molar
ratio
ioniz
lipid
structur
lipid
sterol
peglipid
mix
mrna
mm
citrat
buffer
ph
ratio
aqueou
ethanol
formul
dialyz
mm
triscl
ph
contain
sucros
dialysi
cassett
least
h
formul
concentr
use
amicon
ultra
centrifug
filter
emd
millipor
steril
filter
filter
formul
test
particl
size
rna
encapsul
endotoxin
nm
size
greater
encapsul
euml
endotoxin
virusespowv
lineag
strain
lb
mandl
et
al
isol
origin
human
brain
sampl
powv
lineag
ii
dtv
strain
spooner
isol
origin
adult
deer
tick
ebel
et
al
lgtv
strain
deriv
strain
campbel
pletnev
powv
lb
powv
spooner
lgtv
obtain
world
refer
center
emerg
virus
arbovirus
r
tesh
weaver
univers
texa
medic
branch
powv
strain
isol
tick
collect
wisconsin
describ
brackney
et
al
viru
isol
inocul
cell
homogen
powv
rna
posit
tick
harvest
viru
supernat
cpe
approxim
viru
stock
propag
vero
cell
use
passag
powv
lb
powv
spooner
passag
lgtv
viral
titer
determin
focusform
assay
ffa
vero
cell
describ
previous
brien
et
al
follow
modif
ffa
infect
fix
powv
lb
powv
spooner
lgtv
h
stain
flaviviru
crossreact
mous
mab
zhao
et
al
plasmidsth
plasmid
encod
subgenom
replicon
wnv
lineag
ii
strain
express
gfp
wnvrepgz
report
ansarahsobrinho
et
al
pierson
et
al
plasmid
express
cprme
structur
gene
powv
strain
genbank
access
number
tbev
strain
neudoerfl
genbank
access
number
lgtv
strain
genbank
access
number
ggyv
strain
macquari
island
genbank
clone
express
vector
invitrogen
carlsbad
ca
plasmid
propag
clone
procedur
perform
use
bacteria
grown
c
invitrogen
carlsbad
ca
report
viru
particlesreport
viru
particl
rvp
produc
genet
complement
dnalaunch
subgenom
replicon
cprme
express
plasmid
describ
previous
ansarahsobrinho
et
al
pierson
et
al
briefli
preplat
cell
cotransfect
wnvrepgz
wnv
replicon
express
gfp
report
gene
cprme
express
plasmid
describ
use
fugenehd
promega
accord
manufactur
instruct
transfect
cell
incub
c
supernat
harvest
h
posttransfect
filter
use
syring
filter
store
c
infecti
titer
rvp
assay
use
rajidcsignr
cell
describ
previous
ansarahsobrinho
et
al
pierson
et
al
neutral
assay
rvp
neutral
assay
perform
describ
mukherje
et
al
briefli
rvp
stock
dilut
incub
serial
dilut
serum
h
c
prior
addit
rajidcsignr
cell
infect
carri
c
h
infect
score
percentag
gfpexpress
cell
determin
flow
cytometri
b
focusreduct
neutral
test
frnt
experi
perform
describ
flavivirus
richner
et
al
briefli
serial
dilut
serum
incub
ffu
powv
spooner
h
c
serumviru
mixtur
ad
vero
cell
monolay
incub
h
c
prior
addit
wv
methycellulos
mem
frnt
experi
proceed
describ
ffa
experi
rvp
neutral
assay
frnt
antibodydos
respons
curv
analyz
use
nonlinear
regress
analysi
variabl
slope
graphpad
softwar
data
express
serum
dilut
requir
reduc
infect
half
ec
indic
obtain
ec
valu
resist
fraction
present
bottom
curv
constrain
zero
mous
experimentsimmun
lnp
mrna
vaccin
administ
via
intramuscular
inject
volum
passiv
transfer
studi
serum
dilut
pb
administ
mice
via
intraperiton
inject
total
volum
mice
receiv
dose
serum
powv
sig
vaccin
mice
ml
serum
placebotr
mice
viral
infect
powv
lgtv
perform
via
subcutan
inocul
footpad
ffu
viru
lgtv
powv
spooner
challeng
mg
block
mab
sheehan
et
al
administ
one
day
prior
infect
via
intraperiton
inject
anim
monitor
mortal
weight
loss
clinic
score
evalu
clinic
diseas
follow
powv
infect
mice
assign
one
follow
categori
day
diseas
b
ruffl
fur
c
ruffl
fur
hunch
postur
lethargi
decreas
scurri
activ
e
sick
slow
movement
f
moribund
dead
moribund
mice
euthan
evalu
clinic
diseas
follow
lgtv
challeng
cage
blind
mice
assign
one
follow
categori
day
diseas
b
partial
hindlimb
paralysi
c
complet
paralysi
one
hindlimb
complet
paralysi
hindlimb
e
moribund
dead
moribund
mice
euthan
measur
viral
burdenon
indic
day
postinfect
mice
sacrif
organ
collect
follow
extens
perfus
pb
organ
weigh
homogen
use
magna
lyser
roch
viral
rna
homogen
organ
serum
isol
use
magmax
viral
rna
isol
kit
thermofish
measur
taqman
onestep
quantit
reversetranscript
pcr
rtqpcr
abi
fast
instrument
viral
rna
level
express
scale
viral
rna
equival
per
gram
millilit
comparison
standard
curv
produc
use
serial
dilut
viral
rna
known
quantiti
infecti
viru
order
estim
viral
burden
powv
spooner
primer
describ
platt
et
al
probe
powv
lb
primer
probe
lgtv
primer
probe
statist
analys
perform
use
prism
softwar
version
mac
os
x
graphpad
softwar
log
ec
log
valu
compar
oneway
anova
follow
tukey
multipl
comparison
test
surviv
analysi
kaplanmei
curv
plot
analyz
log
rank
test
bonferroni
correct
multipl
comparison
weight
loss
experi
compar
anova
follow
dunnett
multipl
comparison
test
compar
vaccin
group
placebo
group
sidak
multipl
comparison
test
two
group
compar
viremia
viral
burden
tissu
compar
mannwhitney
test
two
group
compar
kruskal
walli
test
follow
dunn
multipl
comparison
test
two
group
compar
refer
web
version
pubm
central
supplementari
materi
figur
af
mice
receiv
two
dose
powv
sig
jev
sig
vaccin
placebo
challeng
week
second
dose
ffu
ac
powv
lineag
ii
strain
spooner
follow
mab
treatment
n
per
group
df
powv
lineag
strain
lb
n
jev
sig
placebo
n
powv
sig
gi
serum
sampl
collect
mice
receiv
two
dose
powv
sig
placebo
passiv
transfer
naiv
mice
one
day
challeng
ffu
powv
lb
n
per
group
mice
receiv
dose
vaccin
immun
serum
placebo
serum
mice
monitor
mortal
g
day
follow
viral
challeng
statist
signific
determin
log
rank
test
bonferroni
correct
p
p
mean
weight
chang
b
e
h
postvir
challeng
shown
error
bar
repres
sem
statist
signific
determin
use
anova
dunnett
multipl
comparison
test
compar
vaccin
group
placebo
group
ns
signific
p
p
p
p
serum
collect
dpi
measur
viremia
c
f
qrtpcr
bar
indic
median
valu
statist
signific
determin
use
kruskalw
test
dunn
multipl
comparison
test
compar
vaccin
group
placebo
group
p
p
data
panel
collect
two
independ
experi
n
mice
per
group
mice
receiv
one
dose
powv
sig
mrna
vaccin
placebo
vaccin
challeng
day
later
ffu
powv
spooner
follow
mab
treatment
n
per
group
mice
monitor
mortal
day
viral
challeng
statist
signific
determin
log
rank
test
p
b
mean
weight
chang
viru
challeng
shown
error
bar
repres
sem
statist
signific
determin
use
anova
sidak
multipl
comparison
test
p
c
serum
collect
dpi
measur
viremia
qrtpcr
median
viral
titer
shown
statist
signific
determin
mannwhitney
test
p
df
serum
collect
day
postchalleng
assay
neutral
activ
rvp
assay
neutral
titer
shown
bar
indic
median
valu
statist
signific
determin
pair
test
e
f
repres
dose
respons
curv
shown
sera
collect
day
e
day
f
postchalleng
error
bar
repres
sem
two
technic
replic
serum
sampl
collect
two
independ
experi
assay
neutral
potenc
lgtv
powv
sig
jev
sig
n
placebo
n
ggyv
powv
sig
jev
sig
n
placebo
n
median
ec
valu
shown
statist
signific
determin
use
anova
dunnett
multipl
comparison
test
compar
vaccin
placebo
group
ns
signific
p
p
p
serum
sampl
collect
four
independ
experi
assay
neutral
potenc
see
also
figur
